The single-dose Sputnik Light vaccine is said to have demonstrated 70% efficacy against the highly contagious delta variant of the coronavirus.
The Russian Direct Investment Fund (RDIF) said efficacy remains the same during the first three months of vaccination.
The Gamleya Center for Health Sciences has submitted an article analyzing the efficacy of the Sputnik Lite vaccine against the delta variant to the medRxiv preprint server.
The analysis was based on data from 28,000 participants who received a single dose of Sputnik Lite, compared to a control group of 5.6 million individuals who were not vaccinated. The data used in the study was collected in Moscow in July 2021.
“The vaccine is more than 75 percent effective in people under the age of 60. Sputnik Lite also provides very high efficacy against severe disease and hospitalization,” the RDIF said in a statement.
The one-shot Sputnik Lite vaccine is authorized in more than 15 countries, with another 30 countries under registration.
“The delta variant of the coronavirus is one of the most common and dangerous strains of the virus. Data analysis presented in the article by the Gamalaya Center shows that Sputnik Lite remains highly effective even months after vaccination,” said Denis Logunov, deputy director of the Gamalaya Center.
The one-shot vaccine regimen makes it a robust solution for countries with low vaccination rates. He added that Sputnik Light can also be used successfully to maintain existing herd immunity as a booster shot.
On the development, RDIF chief executive Kirill Dmitriev said, “The efficacy of the one-shot Sputnik Light vaccine against the delta version of the coronavirus is much better than that of many two-shot vaccines.”
He added that Sputnik Lite is safe and highly effective when used on a standalone basis and in combination with other vaccines.
“RDIF actively supports research combining Sputnik Lite with other vaccines and has also invited independent international researchers and scientific institutions to collaborate in real-world studies of the safety and efficacy of coronavirus vaccines,” said Dmitriev he said.
Don’t miss a story! Stay connected and informed with Mint.
download
Our App Now!!
.